Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Bajaj Healthcare Ltd

| Statement Of Audited Financial Results For The Quarter And Year Ended On 31 March 2026

Report Source

⬤8th May 26

Summary : Bajaj Healthcare reported reduced FY26 profits due to exceptional items and discontinued operations, while pursuing strategic investments and recommending a dividend.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed: 30,619.95 Lakhs (FY26).
  2. Employee benefits expense: 6,275.26 Lakhs (FY26).
  3. Finance Costs: 2,223.37 Lakhs (FY26).
  4. Total Expenses (Continuing): 55,599.57 Lakhs (FY26).
  5. Total Expenses (Discontinued): 523.40 Lakhs (FY26).
  6. Revenue from operations (Continuing): 61,103.14 Lakhs (FY26).
  7. Total Income (Continuing): 61,816.53 Lakhs (FY26).
  8. Total Income (Discontinued): 11.71 Lakhs (FY26).
  9. Net Cash flow from Operating activities: 5,808.13 Lakhs (FY26).
  10. Net Cash used in Investing activities: (4,777.95) Lakhs (FY26).
  11. Net Cash from financing activities: 2,432.98 Lakhs (FY26).
  12. Cash and Cash equivalents at end of period: 3,723.54 Lakhs (FY26).
  13. Total Assets: 92,321.72 Lakhs (as at 31 March 2026).
  14. Total Equity: 53,300.23 Lakhs (as at 31 March 2026).
  15. Total Liabilities: 39,021.49 Lakhs (as at 31 March 2026).
  16. Non-current assets classified as Held for sale: 6,993.00 Lakhs.
  17. Audited Standalone Financial Results presented.
  18. Genrx not consolidated due to pending NCLT approvals.

Corporate Overview

  1. Middle East (mentioned in context of technical know-how arrangement).
  2. On-going regional instability in Middle East affecting customer timelines.
  3. Customer unable to meet committed timeline for technical know-how.
  4. Pharmaceutical products are interlinked and interdependent.
  5. Deals in pharmaceutical products, formulations, and active pharmaceutical ingredients.
  6. Identified as having one reportable segment: Pharmaceuticals.
  7. Formal and informative, reporting on board decisions and financial results.
  8. Customer in Middle East for technical know-how arrangement.
  9. Pharmaceuticals (formulations and active pharmaceutical ingredients components).
  10. Unutilised balance of 3,184.10 lakhs for Investment in Capital Expenditure.
  11. Acquisition of Genrx Pharmaceuticals Private Limited for Rs. 1,085 lakhs.

Risk Factors

  1. Middle East instability affects customer.
  2. NCLT approval pending for acquisition.
  3. Losses from discontinued operations.
  4. Income reversal due to customer issue.

Key Drivers

  1. Recommended final dividend of 30%.
  2. Significant capital expenditure plans.
  3. Equity shares allotted to promoters.
  4. Acquisition of Genrx Pharmaceuticals.

Auditor’s Report

  1. Unmodified opinion on Audited Standalone Financial Results.
  2. Presents a true and fair view in conformity with Ind AS.

Board Commentary

  1. Appointment of M/s. JCR & Co. LLP as Internal Auditors for FY2026-27.
  2. Re-appointment of M/s. V.J. Talati & Co. as Cost Accountants for FY2026-27.
  3. Recommended a Final Dividend of 30% (Rs. 1.50 per equity share) for FY2025-26.
  4. Subject to shareholder approval at the Annual General Meeting.
  5. On-going regional instability in Middle East affecting customer timelines.
  6. Application with NCLT pending for Genrx Pharmaceuticals acquisition.
  7. Allotment of 20,79,409 fully Paid-up Equity Shares to various categories.
  8. Acquisition of Genrx Pharmaceuticals Private Limited for Rs. 1,085 lakhs.
  9. Unutilised capital expenditure balance of 3,184.10 lakhs.

Corporate Governance

  1. Adherence to Code of Ethics issued by ICAI.
  2. Audit Committee reviewed the financial results.

Management Discussion & Analysis

Risk Control Measures

  1. Reversed income recognition due to customer's inability to meet timelines.

Critical Risks

  1. Regional instability in Middle East impacting customer commitments.
  2. NCLT approval pending for Genrx Pharmaceuticals acquisition.